Details of the Drug
General Information of Drug (ID: DMRDM9S)
| Drug Name |
SCH-602539
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
SCH-602539; UNII-7467O90MW3; CHEMBL1270738; 7467O90MW3; SCH602539; 618385-42-5; SCHEMBL8058894; BDBM50329618; Carbamic acid, N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)furan-6-yl)-, ethyl ester; Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(2,3'-bipyridin-6'-yl)vinyl)-1-methyl-3-oxododecahydronaphtho(2,3-C)furan-6-yl}carbamate; Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)fura
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 475.6 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.1 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Arteriosclerosis | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | BD40 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


